Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486371 | 1.00 | HPGD (0.59) | HPGDSMN1; SMN2CHRNA7ALDH1A1HSD17B10 | |
| SCHEMBL6497255 | 0.85 | CHRNA7 (0.63) | HPGDSMN1; SMN2CHRNA7ALDH1A1TSHR | |
| SCHEMBL6497249 | 0.85 | CHRNA7 (0.63) | HPGDSMN1; SMN2CHRNA7ALDH1A1TSHR | |
| SCHEMBL6488541 | 0.85 | HPGD (0.60) | HPGDSMN1; SMN2CHRNA7ALDH1A1TSHR | |
| SCHEMBL6488534 | 0.85 | HPGD (0.60) | HPGDSMN1; SMN2CHRNA7ALDH1A1TSHR | |
| SCHEMBL6487314 | 0.83 | CHRNA7 (0.50) | HPGDSMN1; SMN2CHRNA7ALDH1A1HSD17B10 | |
| SCHEMBL6487322 | 0.83 | CHRNA7 (0.50) | HPGDSMN1; SMN2CHRNA7ALDH1A1HSD17B10 | |
| SCHEMBL6497048 | 0.82 | ALDH1A1 (0.51) | HPGDSMN1; SMN2CHRNA7ALDH1A1 | |
| SCHEMBL6497050 | 0.82 | ALDH1A1 (0.51) | HPGDSMN1; SMN2CHRNA7ALDH1A1 | |
| SCHEMBL6487632 | 0.81 | CHRNA7 (0.52) | HPGDSMN1; SMN2CHRNA7ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | HPGD 706/4885SMN1; SMN2 1751/4885CHRNA7 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.